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Abstract: Carbon ion radiotherapy (CIRT) is more effective than conventional photon beam radiotherapy in treating 
osteosarcoma (OSA); however, the outcomes of CIRT alone are still unsatisfactory. In this study, we aimed to inves-
tigate whether miR-29b acts as a radiosensitizer for CIRT. The OSA cell lines U2OS and KHOS were treated with 
carbon ion beam alone, γ-ray irradiation alone, or in combination with an miR-29b mimic. OSA cell death as well as 
invasive and migratory abilities were analyzed through viability, colony formation, Transwell, and apoptosis assays. 
miR-29 expression was downregulated in OSA tissues compared to that in normal tissues and was associated with 
metastasis and relapse in patients with OSA. Further, miR-29b was found to directly target the transcription factor 
Sp1 and suppress the activation of the phosphatase and tensin homolog (PTEN)-AKT pathway. Conversely, Sp1 was 
found to attenuate the inhibitory effects of miR-29b in OSA cells. When used in combination with miR-29b mimic, 
carbon ion beam markedly inhibited invasion, migration, and proliferation of OSA cells and promoted apoptosis by 
inhibiting AKT phosphorylation in a Sp1/PTEN-mediated manner. Taken together, miR-29b mimic improved the ra-
diosensitivity of OSA cells via the PTEN-AKT-Sp1 signaling pathway, presenting a novel strategy for the development 
of carbon ion beam combination therapy.
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Introduction
Osteosarcoma (OSA) is the most common 
malignant primary neoplasm of the bone in chil-
dren and young adults [1, 2]. As OSA cells are 
not readily killed by photon beams, convention-
al radiation therapy does not play a major role 
in the treatment of OSA [3, 4]. High linear trans-
fer energy (LET) carbon ion radiotherapy (CIRT) 
is an innovative method in cancer treatment 
resulting in improved quality of life owing to its 
high radiocurability, which is attributable to its 
strong biological impact and more desirable 
dose distribution than that of proton beam and 
photon beam radiation therapies [5, 6]. The 
physical and biological advantages of CIRT 
make it ideal for targeting radioresistant tu- 
mors or tumors located near sensitive organs 
[7, 8]. Over the past 25 years, CIRT has been 
predominantly applied in the treatment of sev-
eral cancers including OSA. According to our 
clinical data, CIRT is an effective and safe 
modality to treat unresectable OSA of the trunk; 
therefore, it offers appreciable long-term func-
tional results and a decent survival advantage 
without accompanying morbidities [9-13]. We 
previously explored how and why CIRT alone or 
in combination with DNA-damaging drugs such 
as gemcitabine and cisplatin is more effective 
in killing radioresistant cancer stem cells (CSCs) 
than photon beam therapy [14-20]. However, 
limitations exist in the application of CIRT alone 
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or in combination with existing anticancer dru- 
gs for the treatment of more advanced and 
aggressive cancers [21]. As the overall survival 
of patients with OSA is still poor, an effective 
novel molecular targeted combination therapy 
is warranted for expanding the therapeutic 
effects of CIRT. 
MicroRNAs (miRNAs) are endogenously ex- 
pressed on coding RNA molecules that regulate 
gene expression negatively at the post-tran-
scriptional level by base-pairing with the 
untranslated region (UTR) of the target mRNAs 
[22, 23]. A single miRNA binds and regulates 
nearly 100 different transcripts [24, 25]. 
Therefore, miRNAs are deemed the master reg-
ulators of gene expression, influencing majority 
of cell events and activities, metabolism, infec-
tion, as well as cancer [26-28]. The anti-tumor 
effects of miRNAs have been demonstrated by 
targeting the miRNA network, indicating a great 
therapeutic potential of miRNAs in cancer treat-
ment [29, 30]. Thus, there is a need for devel-
oping combination therapy involving carbon ion 
beam and new potential molecular targeted 
drugs such as miRNA mimics/antagomirs. 
Recently, several studies have shown that miR-
29b, a miR-29 family member, is altered in sev-
eral human cancers and serves as a critical 
tumor suppressor [31]. The enforced expres-
sion of miR-29b in cancer cells impedes extra-
cellular matrix remodeling [32], tumor-suppres-
sor promoter methylation [30], and antiapop-
totic signaling [33, 34]. In addition, the expres-
sion of miR-29b and miR-29a is downregulated 
via activation of survival-promoting and multi-
ple growth signaling pathways such as the ones 
that involve c-myc, Hedgehog, and NF-kB [35]. 
miR-29b overexpression induce apoptosis in 
vitro and anti-tumor effects in vivo in acute 
myeloid leukemia and rhabdomyosarcoma [36-
46]. We previously reported that downregula-
tion of miR-29c expression resulted in en- 
hanced expression of KLF4, a transcription fac-
tor that maintains breast CSCs, leading to 
the inhibition of CSC production. This finding 
suggested that miR-29c negatively regulates 
breast CSCs [47]. Recently, we have demon-
strated that zoledronic acid (ZOL), one of the 
bisphosphonates, is a drug used to treat osteo-
porosis and bone metastasis, effectively en- 
hanced carbon ion beam radiosensitivity ac- 
companied with upregulation of miR-29b ex- 
pression in OSA cells [48].
In this study, we aimed to elucidate the molecu-
lar mechanisms underlying miR-29b-induced 
carbon ion beam radiosensitization of OSA 
cells.
Materials and methods 
Cell culture
U2OS and KHOS/NP OSA cells were obtain- 
ed from the American Type Culture Collection 
and cultured in Dulbecco’s modified Eagle 
medium (DMEM) [before being supplemented 
with fetal bovine serum (FBS; WelGene), 
1% (v/v) penicillin-streptomycin, and 10% FBS 
(Gibco®; Thermo Fisher Scientific, Waltham, 
MA)] in a humidified incubator at 37°C and 5% 
CO2. OSA tissues and matched non-tumor tis-
sues were derived after obtaining informed 
consent from 14 patients who were operated at 
the Korea Institute of Radiological and Medical 
Sciences (Institutional Review Board Approval 
Number K-1603-001-001). Primary cell cul-
tures were established from this tissue. Simply 
put, the tissue was finely chopped into a slurry 
with a blade, washed with phosphate buffered 
saline (PBS), and centrifuged at 1000 rpm for 3 
minutes. The supernatant is then discarded 
and the pellet resuspended in serum-free 
Dulbecco-modified Eagle’s medium (DMEM, 
WelGene, Daegu, South Korea) containing 
0.05-0.1% (w/v) Type I collagenase (Gibco®, 
Life Technologies). After 2 h, cells were washed 
clean with PBS and maintained in DMEM con-
taining 20% (v/v) FBS. 
Reagents
Anti-p21 (sc-397), anti-β-actin (sc-81178), anti-
Slug (sc-166476), and anti-Snail (sc-10432) 
antibodies were purchased from Santa Cruz 
Biotechnology (Dallas, TX). Anti-cleaved poly-
ADP ribose polymerase (PARP) (#9541), CDK6 
(#3136), MCL-1 (#4572), Sp1 (#9389), PTEN 
(#9559) p-AKT (Ser473) (#4060), total AKT 
(#9272), p-4EBP1 (S65) (#9451) and p-GSK-3b 
(Ser9) (#9336) were purchased from Cell 
Signaling Technology (Danvers, MA).
Irradiation
The cells were irradiated with carbon ion beams 
accelerated by the heavy ion medical accelera-
tor in Chiba at the National Institute of Ra- 
diological Sciences. The details regarding the 
beam characteristics of carbon ion beams, bio-
logical irradiation procedures, and dosimetry 
are described elsewhere [30]. Briefly, we used 
290 MeV/nucleon carbon ion beams with dose 
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average LET of 50 KeV/µm at the center of 
spread-out Bragg peak. As a reference, we irra-
diated cells with Cs-137 γ-rays (Atomic Energy 
of Canada, Ltd., Ontario, Canada) or X-rays 
(Titan-320, GE Co., USA) at a dose rate of 2.45 
or 3.81 Gy/min, respectively, at the Korea 
Institute of Radiological and Medical Sciences 
and/or NRIS. The cells were irradiated with 
γ-rays (2, 4, or 6 Gy) or carbon ion beams (1, 2, 
or 3 Gy).
miRNA and transient transfection
miR-29b mimic and control mimic were pur-
chased from Bioneer (Daejeon, South Korea). 
The cells were transfected with 60 nM control 
or miR-29b mimic for 24 h by using G-fectin 
miRNA Transfection Reagent. Then, the cells 
were transfected with si-SP1 using Lipofec- 
tamine 2000 (Invitrogen, Carlsbad, CA) accord-
ing to manufacturer’s instructions.
Cell viability assay
The cells were seeded in 96-well plates at a 
density of 5000 cells/well and incubated for 
the time points indicated therein. To quantify 
cell viability, a culture medium containing an 
equal amount of EZ-Cytox reagent was added 
to the cells and incubated for 4 h. Then, the 
cells were treated with miR-29b mimic for 24 h 
and seeded and irradiated. Cell viability was 
measured after 48 h using a Multiskan EX 
instrument (Thermo Fisher Scientific) at 450 
nm.
Colony formation assay
At 24 h post-transfection with miR-29b mimic, 
the cells were reseeded and incubated for 7-9 
days. The colonies were then fixed with metha-
nol, stained with 0.4% crystal violet (Sigma-
Aldrich, St. Louis, MO), and counted.
Western blotting
OSA cells were treated with miR-29b or irradia-
tion and incubated for 24 or 48 h. The cells 
were then lysed with RIPA buffer. Next, the pro-
teins were separated by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis and trans-
ferred to nitrocellulose membranes. The mem-
branes were blocked with 5% (v/v) skim milk in 
PBS and 0.1% Tween 20 and then incubated 
with the indicated antibodies (1:1,000), fol-
lowed by secondary antibodies (1:1,000). Fi- 
nally, the blots were developed using the Pierce 
Enhanced Chemiluminescence Western Blo- 
tting Substrate (Thermo Fisher Scientific) and 
scanned.
Detection of apoptotic cells by Annexin V stain-
ing
The cells were treated with miR-29b and incu-
bated for 48 h. Then, the cells were washed 
with ice-cold PBS, trypsinized, and suspended 
in 1 × binding buffer at a density of 1 × 106 
cells/mL. Cell suspension aliquots (100 μL) 
were mixed with 5 μL annexin V FITC and 10 μL 
propidium iodide stock solution (50 μg/mL in 
PBS) through gentle vortexing and incubated 
for 15 min at room temperature. To each sam-
ple, 1 × buffer (400 μL) was added and ana-
lyzed using FACScan flow cytometer. At least 
10000 cells were counted for all samples, and 
data analysis was performed using CellQuest 
software.
Transwell assays
The invasive and migratory abilities of OSA ce- 
lls were determined using Transwell chambers 
(Millipore) according to the manufacturer’s 
instructions. The cells were placed on the up- 
per chamber of Transwell containing 150 μL of 
medium that was either untreated or treated 
with irradiation, miR-29b, or miR-29b along 
with irradiation for 24 h. The cells that migrated 
through the Matrigel/gelatin-coated membrane 
were stained using a cell stain solution provid-
ed with the Transwell chamber assay kit 
(Chemicon, Millipore).
DNA constructs
A DNA fragment of the Sp1 3’-UTR that con-
tained the putative binding site of miR-29b was 
amplified with PCR by using the following prim-
ers: 5’-GTGTCTAGAGATTAGGGGAGGGTTGGAG- 
3’ (forward) and 5’-GTGGAATTCGTCCAAAAGG- 
CATCAGGG-3’ (reverse), before cloning into the 
pGL3luc vector. For creating the mutant re- 
porter, four nucleotide mutations were induced 
in the putative miR-29b binding site using 
EZchange™ Multi Site-directed Mutagenesis 
Core Kit (Enzynomics, Daejeon, South Korea). 
The primer sequences used were 5’-GGT- 
TCTTCTGGGGacgaAATCAGGCCCCTG-3’ (forwa- 
rd) and 5’-CAGGGGCCTGATTtcgtCCCCAGAA- 
GAACC-3’ (reverse). The vectors were confirmed 
by sequencing (Bioneer).
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Luciferase assay
miR target prediction sites were used to predict 
Sp1 as a direct target gene of miR-29b. 
According to these prediction sites, Sp1 was 
included as the potential target. The cells were 
seeded in a 24-well plate. Then, Sp1 3’-UTR 
mutant plasmids or reporter constructs were 
co-transfected with miR-29b as well as pRL-
CMV-Renilla internal control plasmid using 
Lipofectamine 2000. The Dual-GloTM Luci- 
ferase Assay System was used to determine 
the luciferase activity. The relative activities 
were normalized to Renilla luciferase activity.
Plasimd transient transfection
Prior to transfection, cells were plated on 6-well 
plates. After reaching 80% confluence, it was 
transfected with 2 μg of plasmid using Li- 
pofectamine 2000 (Invitrogen) according to the 
manufacturer’s procedure. 
RNA extraction and quantitative reverse-tran-
scription PCR
Total RNA was isolated using TRIzol reagent 
(Invitrogen). Quantitative reverse-transcription 
PCR was performed using KAPA Biosystems’ 
KAPA SYBR FAST qPCR kit according to the 
manufacturer’s instructions.
Caspase activity assay
Caspase activity was measured using the cas-
pase family activity assay kits, according to the 
manufacturer’s instructions.
Statistical analysis
Experiments involving cell culture were per-
formed in triplicate. The data were expressed 
as values of mean ± standard deviation. The 
statistical differences between different groups 
were analyzed using ANOVA and Student’s 
t-test (two-tailed). The following P-values were 
considered significant: *P < 0.05, **P < 0.01, 
and ***P < 0.001.
Results
miR-29b expression is downregulated in OS 
specimens and cell lines
To understand the signatures of differentially 
expressed genes (DEGs), we performed miR-
29b gene ontology analysis. Accordingly, these 
DEGs were significantly enriched in the pro-
cesses of cell death and negative regulation of 
cell proliferation (Figure 1A). qRT-PCR analysis 
revealed that miR-29b expression in primary 
tumor tissues was significantly enhanced when 
compared to that in matched non-tumor tis-
sues (IRB: No. K-1603-001-001) (Figure 1B).
Figure 1. A. DAVID function analysis for the miR-29b targeted genes of pathways 
in OSA. The horizontal axis represented p-value transformed by -log2 and the gene 
number of each cluster respectively. The vertical axis represented the functions of 
the target genes. Only the most significantly enriched clusters were shown. B. Rela-
tive expression of miR-29 in matched primary OSA tissues and non-tumor tissues; 
*P < 0.05. 
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miR-29b inhibits OSA cell proliferation, sur-
vival, migration, and invasion via Sp1 suppres-
sion
miR-29b was transfected into KHOS and U2OS 
cells, which was confirmed by qRT-PCR analysis 
after 24 h (Figure 2A). To determine whether 
miR-29b suppresses the oncogenic phenotype 
of OSA cells, we performed gain-of-function 
assays in OSA cells using miR-29b mimics. As 
shown in Figure 2B, miR-29 mimic significantly 
inhibited OSA cell growth from 48 h after trans-
fection. We also found that miR-29b mimic sig-
nificantly inhibited colony formation and cell 
proliferation in KHOS and U2OS cells (Figure 
2C, 2D). Interestingly, growth inhibition was 
associated to upregulation of the cell-cycle 
inhibitor p21 and downregulation of pro-surviv-
al factors CDK-6 and MCL-1, both observed 24 
h after cell transfection with miR-29b. Impor- 
tantly, miR-29b-induced apoptosis was found 
to be associated with PARP activation, as evi-
denced by increased cleavage using Western 
blotting (Figure 2E). And transfection after 48 h 
resulted in a substantial accumulation of cell 
populations in G1 and a decrease in cell cycle S 
phase populations (Figure 2F). Furthermore, 
we found that miR-29b mimic suppressed the 
migratory and invasive ability of KHOS and 
U2OS cells (Figure 2G). Data regarding the cir-
cRNA/miRNA/mRNA interaction network of 
miR-29b, obtained using Cytoscape, were inte-
grated to construct a cancer-related signaling 
network that includes miR-29b target genes. 
Most target genes in the network were consid-
ered closely associated with cell proliferation 
and tumor growth (Figure 2H). Thus, these find-
ings indicate that miR-29b significantly inhibits 
proliferation, survival, migration, and invasion 
of OSA cells.
Sp1 is a direct target of miR-29 and miR-29 
suppresses OSA growth and invasion through 
Sp1
The predicted binding site of miR-29b was iden-
tified in the 3’-UTR of Sp1 mRNA. Therefore, we 
first constructed luciferase reporter plasmids 
containing the wild-type or mutant miR-29b tar-
get site in the Sp1 3’-UTR sequence (Figure 
3A). KHOS and U2OS cells were co-transfect- 
ed with miR-29b expression and reporter plas-
mids. miR-29b expression significantly decrea- 
sed firefly luciferase activity but not mutant 
reporter activity, in the presence of wild-type 
3’-UTR (Figure 3B). Furthermore, miR-29b over-
expression for 48 h significantly decreased 
mRNA and protein levels of Sp1 compared with 
those in the control group (Figure 3C, 3D), indi-
cating that miR-29b suppressed Sp1 expres-
sion by binding to its target site at the 3’-UTR of 
Sp1. We also found that Sp1 overexpression 
was associated with reduced miR-29b levels 
(Figure 3E). And Sp1 silencing led to inhibition 
of OSA cell growth and cell proliferation, and 
Sp1 overexpression showed the opposite result 
(Figure 3F-H). These results demonstrate that 
miR-29 suppressed the growth of OSA cells by 
directly downregulating Sp1. Thus, our findings 
show that miR-29 forms an auto-regulatory 
loop with Sp1 to regulate OSA cell aggressive- 
ness. 
miR-29b activates the PTEN/AKT pathway by 
suppressing the Sp1 loop in OSA cells
miR-29b inhibits proliferation, migration, and 
invasion of tongue tumor cells via phosphatase 
and tensin homolog (PTEN)-AKT-SP1 pathway 
[30]. To examine whether miR-29b acts as a 
potential tumor suppressor in OSA cells, we 
performed pathway analysis of PTEN-AKT–SP1 
and found that miR-29b significantly increased 
PTEN protein levels and downregulated phos-
phorylated AKT expression without affecting 
the total AKT levels (Figure 4A). We next trans-
fected KHOS and U2OS cells with miR-29b 
expression plasmid and a luciferase reporter 
containing the wild-type or mutant PTEN pro-
moter. A marked increase in the luciferase/
Renilla ratio was found in cells transfected with 
the wild-type PTEN promoter reporter but not in 
those with the mutant reporter (Figure 4B). To 
ascertain whether miR-29b upregulates PTEN 
expression by targeting Sp1, we determined 
whether knockdown of endogenous Sp1 activi-
ty mimics the effects of exogenous miR-29b 
overexpression. There was a marked increase 
in the luciferase/renilla ratio in cells transfect-
ed with the wild-type PTEN promoter reporter, 
but not with the mutant reporter (Figure 4C). 
As expected, siRNA-mediated Sp1 knockdown 
in OSA cells increased PTEN expression and 
consequently decreased AKT phosphorylation 
(Figure 4D). In addition, PI3K inhibition by 
LY294002 increased miR-29b and decreased 
Sp1 and p-AKT (S473) protein levels, so miR-
29b was negatively regulated by PI3K/AKT 
(Figure 4E). Overexpression of AKT suppressed 
the miR-29b-dependent decrease in Sp1 mRNA 
levels (Figure 4F). Transfection of the synthetic 
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Figure 2. miR-29b inhibits OSA cell proliferation, survival, migration, and invasion. (A) qPCR analysis showing relative miR29b expression; ***P < 0.001. (B) Trypan 
blue assay of two OSA cell lines transfected with miR-29b or scrambled oligonucleotides (Scr); *P < 0.05, **P < 0.01, ***P < 0.001. (C, D) Colony formation assay 
(upper) and MTT assay (lower) using the two OSA cell lines after transfection with synthetic miR-29b or Scr; *P < 0.05, **P < 0.01. (E) Immunoblotting using the 
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indicated antibodies 48 h after transfecting the two OSA cell lines with synthetic miR-29b or Scr. (F) Inhibition of cell cycle progression by overexpression of miR-29b. 
Two OSA cell lines were transfected as in (A). Cells were stained with propidium iodide (PI) at 48 h post-transfection and analyzed with FACS. *P < 0.05, (G) Migration 
and invasion of OSA cells decreased with miR-29b overexpression. Photo micrographs of Transwell migration and invasion of OSA cells transfected for 24 h; *P < 
0.05. (H) Establishment of a circRNA/miRNA/mRNA interaction network of pathways in cancer. 
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Figure 3. miR-29b inhibits Sp1 expression. A. Wild-type AKT (WT) and mutant (MUT) forms of putative miR-29 target sequences of the Sp1 3’-UTR. B. Analysis of the 
luciferase activity of psicheck-2-Sp1 3’-UTR WT and MUT vectors in OSA cells; **P < 0.01. C. Sp1 mRNA levels in the indicated cells were analyzed by qRT-PCR; *P < 
0.05. D. Sp1 protein levels in the indicated cells were examined by western blotting. E. miR-29b levels were analyzed by qRT-PCR in OSA cells transfected with Sp1; 
*P < 0.05. F. Sp1 protein levels were detected by western blotting analysis after transfection of KHOS and U2OS cells with si-Sp1 and Sp1. G, H. Trypan blue assay 
and MTT assay were performed using KHOS and U2OS cells transfected with si-Sp1 and Sp1; *P < 0.05.
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miR-29b mimic also resulted in reduced phos-
phorylation of the AKT substrate glycogen syn-
thase kinase-3b (p-GSK-3b (S9)) (Figure 4G). 
Moreover, we provided preliminary evidence 
that transfection of cells with miR-29b mimics 
inhibits mTOR-mediated signals, as evidenced 
by the reduced p-4EBP1 (S65) (Figure 4G). 
These findings demonstrate that miR-29b ac- 
ts as a negative regulator of the PI3K/AKT 
pathway. 
Carbon ion beam irradiation in combination 
with miR-29b mimic decreases OSA cell viabil-
ity and increases apoptosis induction 
To evaluate the effects of miR-29b on the radio-
sensitivity of OSA cells, cell viability assays 
were performed as mentioned in Methods. OSA 
cells were first treated with carbon ion beam 
alone, γ-ray alone, or in combination with miR-
29b pretreatment for 24 h. miR-29b pretreat-
ment significantly reduced the cell growth of 
OSA cells following 72 h of irradiation (Figure 
5A), indicating that miR-29b markedly enhanc-
es the radiosensitivity of OSA cells. In addition, 
carbon-ion beam + miR-29b mimic reduced the 
survival fraction of OSA cells significantly more 
than carbon ion beam irradiation alone (Figure 
5B). We also found that apoptotic events 
induced by combination treatment of carbon 
ion beam irradiation and miR-29b mimic were 
associated with increased caspase-3 activa-
tion and activated PARP (Figure 5C, 5D). 
Consistent with our assumption, antagomiR-
29b-expressing cells showed proliferative char-
acteristics and were less susceptible to carbon 
ion beam-induced growth inhibition (Figure 5E).
Carbon ion beam irradiation combined with 
the miR-29b mimic enhances radiosensitivity 
via Sp1 suppression in OSA cells 
To investigate the molecular mechanism under-
lying the enhanced carbon ion radiosensitivity 
of OSA cells after treatment with the miR-29b 
mimic, we examined the changes in Sp1 mRNA 
and protein levels in OSA cells. Compared with 
γ-ray irradiation, carbon ion beam irradiation 
dramatically downregulated Sp1 expression in 
KHOS cells and U20S cells (Figure 6A). In addi-
tion, carbon ion beam irradiation significantly 
upregulated miR-29b expression compared 
with γ-ray irradiation in both KHOS and U2OS 
cells (Figure 6B). As shown in Figure 6C, miR-
29b overexpression along with siSP1 treatment 
caused a significant inhibition in cell growth 
and invasive ability of both OSA cell lines 
starting at 48 h after transfection (Figure 6D). 
Western blotting results further confirmed that 
transcription factors associated with epithelial-
mesenchymal transition proteins were dramati-
cally decreased in carbon ion beam + miR-
29b-treated cells (Figure 6E). Next, we exam-
ined the effect of mithramycin A, a Sp1-specific 
inhibitor, on the carbon ion radiosensitivity of 
OSA cells (Figure 6F). Mithramycin A significant-
ly reduced the growth of OSA cells after a car-
bon ion beam. Furthermore, carbon ion irradia-
tion showed a significant inhibition of cell viabil-
ity than gamma-ray irradiation. These findings 
indicate that Sp1 is essential for the radioresis-
tance of OSA cells and that decreased Sp1 
expression may be involved in miR-29b-in-
duced carbon ion radiosensitivity.
Discussion
In this study, we aimed to elucidate the molecu-
lar mechanism underlying miR-29b-induced 
carbon ion beam radiosensitization of OSA 
cells. We found that carbon ion beam irradia-
tion combined with miR-29b mimic significantly 
increased caspase-3 activation compared with 
that of carbon ion beam irradiation alone, sug-
gesting that the enhanced radiosensitization of 
miR-29b may be partially due to an increased 
induction of apoptosis. Regarding the molecu-
lar mechanisms underlying the radiosensitizing 
Figure 4. miR-29b activates the PTEN/AKT pathway via Sp1 suppression. A. PTEN, p-AKT, and AKT protein levels 
were analyzed by western blotting of two OSA cell lines transfected with miR-29b. PTEN gene expression in Scr- and 
miR-29b-transfected cells by qRT-PCR; *P < 0.05. B. The Sp1 binding site (middle) on the PTEN promoter (lower).
Mutation of Sp1 binding site (upper). C. Relative luciferase activity in control or miR-29b-expressing OSA cell lines 
co-transfected with a wild-type or mutant PTEN promoter; **P < 0.01. D. PTEN, p-AKT, and AKT protein levels were 
analyzed by western blotting of two OSA cell lines transfected with si-Sp1 RNA. PTEN gene expression in Scr- and 
si-Sp1-transfected cells by qRT-PCR; *P < 0.05; **P < 0.01. E. qRT-PCR of miR-29b in OSA cell lines treated with 20 
mM LY294002 or vehicle (DMSO) for 48 h. Immunoblotting shows the protein levels of Sp1 and phosphorylated AKT 
at S473 in LY294002-treated cells; *P < 0.05, **P < 0.01. F. Cells were transfected with pcDNA.3.1-HA-myr-AKT 
dominant active construct or the empty vector pcDNA3.1 and analyzed after 48 h for Sp1 expression levels by qRT-
PCR; **P < 0.01. G. The indicated antibodies were used for western blotting of OSA cells transfected with miR-29b. 
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Figure 5. Carbon ion beam irradiation combined with miR-29b mimic decreased OSA cell survival and enhanced apoptosis induction. A. Trypan blue assay of OSA 
cells after transfection with synthetic miR-29b or carbon ion or X-ray irradiation + miR-29b mimic combination treatment; *P < 0.05, **P < 0.01. B. Colony formation 
assay of OSA cells after transfection with synthetic miR-29b or carbon ion or X-ray irradiation + miR-29b mimic combination treatment. C. Analysis of caspase activ-
ity in both OSA cell lines 48 h after carbon ion beam treatment alone or in combination with miR-29b. Data were collected using Multiskan EX at 405 nm (upper); 
*P < 0.05, **P < 0.01. D. Cleaved-PARP protein level was analyzed by western blotting of two OSA cell lines with the indicated treatment (lower). E. Two OSA cells 
were transduced with the empty vector or miR-29b mimic or antagomiR-29b and then treated with irradiation for 48 h. Viable cells were determined using trypan 
blue assay; **P < 0.01.
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effects of miR-29b, the miR-29b-Sp1 loop has 
been shown to play a major role in this 
process.
First, we analyzed miR-29b expression in pri-
mary OSA and non-tumors from 14 patients 
and found that miR-29b expression was lower 
in tumor tissues than in the corresponding 
non-tumor tissues. Our recent study involving 
miRNA microarray profiling from four paired 
samples of OSA versus matched nonmalignant 
tissues also showed the same results. This 
finding is also consistent with previous reports 
demonstrating that miR-29b expression is 
decreased in various tumors, such as multiple 
myeloma, lung tumors, and gastric cancer, and 
acts as a tumor suppressor gene [28, 35, 
38-46]. Then, we confirmed that treatment with 
miR-29b mimic alone significantly inhibited cell 
proliferation and survival and suppressed cell 
migration and invasion, accompanied by en- 
hanced p21 expression and decreased CDK6 
and MCL1 expression in KHOS and U2OS cells. 
This finding is consistent with previous reports 
demonstrating that miR-29b acts as a tumor 
suppressor in various cancers, such as pros-
tate, breast, glioblastoma, and lung cancers 
[40-43]. Moreover, the miR-29b mimic signifi-
cantly reduced Sp1 expression by binding to its 
target site at the 3’-UTR of Sp1. In contrast, Sp1 
overexpression reduced miR-29b expression, 
whereas silencing of Sp1 increased miR-29b 
levels, consequently suppressing the prolifera-
tion, migration, and invasion of OSA cells. These 
results demonstrate that miR-29b inhibits the 
growth and invasion of OSA cells, at least in 
part, by downregulating Sp1. Therefore, we 
speculate that a miR-29b-Sp1 regulatory feed-
back loop occurs in OSA cells and radiation-
treated OSA cells, and it could be a potential 
therapeutic target. This finding is in agreement 
with previous findings where miR-29b was 
found to be negatively correlated with Sp1 
expression [44-46]. 
In the present study, miR-29b mimic signifi-
cantly increased PTEN expression and reduced 
phosphorylated AKT levels without affecting 
total AKT levels. Sp1 knockdown increased 
PTEN expression and subsequently decreased 
AKT phosphorylation in OSA cells. Moreover, 
inhibition of PI3K by LY294002 decreased Sp1 
protein expression and increased miR-29b lev-
els as further proof for the negative regulation 
exerted by PI3K/AKT on miR-29b expression. 
These findings demonstrate that miR-29b acts 
as a negative regulator of the PI3K/AKT path-
way. miR-29b inhibits AKT phosphorylation 
by suppressing PI3K and increasing PTEN 
expression [42, 43]. Carbon ion beam irradia-
tion effectively inhibited Sp1 expression. 
Carbon ion beam irradiation in combination 
with miR-29b mimic showed stronger cell killing 
effects and suppression of OSA cell migration 
and invasion than γ-ray irradiation. These 
results present novel evidence on the major 
molecular mechanisms underlying the enhan- 
cement of carbon ion beam radiosensitivity of 
OSA cells by miR-29b.
In summary, carbon ion beam irradiation in 
combination with miR-29b mimic efficiently 
suppressed the invasion, migration, and prolif-
eration of OSA cells and promoted apoptosis by 
inhibiting AKT phosphorylation via Sp1/PTEN-
AKT pathway (Figure 7). The miR-29b mimic 
enhanced radiosensitivity of OSA cells to car-
bon ion beam irradiation via PTEN-AKT-Sp1 
pathway, suggesting a strategy for the develop-
ment of novel combination CIRT.
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